Key Facts
- 3 sites; UK, Germany and US
-
| No of employees: |
| UK: 79 (46 in R&D) |
| Germany: 41 (25 in R&D) |
| US: 49 (4 in R&D) |
- Comprehensive patent portfolio
- 2009 Revenue of £26.6m, representing growth of 50% on 2008
- Year-end net funds of £30.5m
Vision
Principal 2010 Operating Goals:
- Complete recruitment in the CM3 Phase I clinical trials in Type 2 Diabetes.
- Commence recruitment in the CM3 Phase II clinical trial.
- File regulatory submission (PMA) for the DC Bead in Japan.
- Complete recruitment in the clinical trial supporting the DC Bead regulatory submission for China.
- Updates from our principal Drug-Eluting Bead clinical trials, which include SPACE, PARAGON II and PARAGON Louisville.
2010 Guidance:
- Revenue in the range of £28m to £32m (13% increase on 2009 at the mid-point; 21% CC).
- Pay a dividend of 6.25 pence per share in May; an increase of 25%.
- Closing cash of £25m after payment of the dividend of £2.5m.